9-Anthraldehyde-N(4)-methylthiosemicarbazone (MeATSC), potassium (E)-2-(2-hydroxybenzylideneamino)-3-(1H-indol-3-yl)propanoate (K[(Sal-L-tryp)] and 2-(2-hydroxybenzylamino)-3-(1H-indol-3-yl)propanoic acid (the reduced Schiff base) were prepared using known synthetic procedures. Two novel thiosemicarbazone ligands, (E)-N-ethyl-2-(4-hydroxy-3-methoxybenzylidene)hydrazinecarbothioamide (N-Ethhymethohcarbthio) and (E)-N-ethyl-2-(1-(thiazol-2-yl)ethylidene)hydrazinecarbothioamide (acetylethTSC), were also prepared. All ligands were characterized by FT IR and electrochemistry. N-Ethhymethohcarbthio were characterized by elemental analysis whereas the reduced Schiff base and K[(Sal-L-tryp)] were characterized by ESI MS. X-ray crystallography was also used to characterize acetylethTSC. The ligands were then reacted with [VO(Sal-L-tryp)(H2O)] (1) (Sal-L-tryp = N-salicylidene-L-tryptophanate) to produce the novel complexes, [VO(Sal-L-tryp)(MeATSC)].1.5C2H5OH (2), [VO(Sal-L-tryp)(N-Ethhymethohcarbthio)].H2O (3), and [VO(Sal-L-tryp)(acetylethTSC)].0.75C2H5OH (4), respectively. All complexes were characterized by elemental analysis, ESI MS, IR, UV-visible, 1H and 13C NMR spectroscopy, and electrochemistry. Oxidized DMSO and DMSO-d6 solutions of each complex were also characterized by ESI MS and 1H NMR spectroscopy. [VO(Sal-L-tryp)(MeATSC)].1.5C2H5OH, [VO(Sal-L-tryp)(N-Ethhymethohcarbthio)].H2O, and [VO(Sal-L-tryp)(acetylethTSC)].0.75C2H5OH were observed to exhibit anti-proliferative activity against three colon cancer cell lines, HTC-116, Caco-2, and HT-29. When the anti-proliferative effects were compared with that of non-cancerous colonic myofibroblasts, less inhibition was observed. The results obtained suggest that these compounds can be used as potential chemotherapeutic agents.
","abstract_html":"<p>9-Anthraldehyde-N(4)-methylthiosemicarbazone (MeATSC), potassium (E)-2-(2-hydroxybenzylideneamino)-3-(1H-indol-3-yl)propanoate (K[(Sal-<em>L</em>-tryp)] and 2-(2-hydroxybenzylamino)-3-(1H-indol-3-yl)propanoic acid (the reduced Schiff base) were prepared using known synthetic procedures. Two novel thiosemicarbazone ligands, <em>(E</em>)-<em>N</em>-ethyl-2-(4-hydroxy-3-methoxybenzylidene)hydrazinecarbothioamide (<em>N</em>-Ethhymethohcarbthio) and (<em>E</em>)-<em>N</em>-ethyl-2-(1-(thiazol-2-yl)ethylidene)hydrazinecarbothioamide (acetylethTSC), were also prepared. All ligands were characterized by FT IR and electrochemistry. <em>N</em>-Ethhymethohcarbthio were characterized by elemental analysis whereas the reduced Schiff base and K[(Sal-<em>L</em>-tryp)] were characterized by ESI MS. X-ray crystallography was also used to characterize acetylethTSC. The ligands were then reacted with [VO(Sal-<em>L</em>-tryp)(H2O)] <strong>(1) </strong>(Sal-<em>L</em>-tryp = <em>N</em>-salicylidene-<em>L</em>-tryptophanate) to produce the novel complexes, [VO(Sal-<em>L</em>-tryp)(MeATSC)].1.5C2H5OH <strong>(2)</strong>, [VO(Sal-<em>L</em>-tryp)(<em>N</em>-Ethhymethohcarbthio)].H2O <strong>(3)</strong>, and [VO(Sal-<em>L</em>-tryp)(acetylethTSC)].0.75C2H5OH <strong>(4)</strong>, respectively. All complexes were characterized by elemental analysis, ESI MS, IR, UV-visible, 1H and 13C NMR spectroscopy, and electrochemistry. Oxidized DMSO and DMSO-d6 solutions of each complex were also characterized by ESI MS and 1H NMR spectroscopy. [VO(Sal-<em>L</em>-tryp)(MeATSC)].1.5C2H5OH, [VO(Sal-<em>L</em>-tryp)(<em>N</em>-Ethhymethohcarbthio)].H2O, and [VO(Sal-<em>L</em>-tryp)(acetylethTSC)].0.75C2H5OH were observed to exhibit anti-proliferative activity against three colon cancer cell lines, HTC-116, Caco-2, and HT-29. When the anti-proliferative effects were compared with that of non-cancerous colonic myofibroblasts, less inhibition was observed. The results obtained suggest that these compounds can be used as potential chemotherapeutic agents.</p>","abstract_has_math":false,"creators":["Lewis, Nerissa Abigail"],"institution":null,"degree_name":"Master of Science (MS)","degree_level":"Masters Thesis","degree_discipline":"Chemistry and Biochemistry","degree_department":null,"school":null,"contributors":["Alvin A. Holder","Douglas S. Masterson","Wujian Miao"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2011,"date_issued":"2011-12-01T08:00:00Z","date_published":"2011-12-01T08:00:00Z","updated_at":"2026-07-24T05:44:41Z","subjects":["vitro studies","novel vanadium (IV) complexes","schiff bases","thiosemicarbazone ligands","Chemistry"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"https://aquila.usm.edu/masters_theses/212","outbound_label":"Repository record","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Alvin A. Holder","Douglas S. Masterson","Wujian Miao"]},{"key":"dc:creator","label":"Author","values":["Lewis, Nerissa Abigail"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.available","label":"Dc Date Available","values":["2016-08-12T07:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Chemistry and Biochemistry"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Masters Thesis"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Master of Science (MS)"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["vitro studies","novel vanadium (IV) complexes","schiff bases","thiosemicarbazone ligands","Chemistry"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://aquila.usm.edu/masters_theses/212"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["9-Anthraldehyde-N(4)-methylthiosemicarbazone (MeATSC), potassium (E)-2-(2-hydroxybenzylideneamino)-3-(1H-indol-3-yl)propanoate (K[(Sal-L-tryp)] and 2-(2-hydroxybenzylamino)-3-(1H-indol-3-yl)propanoic acid (the reduced Schiff base) were prepared using known synthetic procedures. Two novel thiosemicarbazone ligands, (E)-N-ethyl-2-(4-hydroxy-3-methoxybenzylidene)hydrazinecarbothioamide (N-Ethhymethohcarbthio) and (E)-N-ethyl-2-(1-(thiazol-2-yl)ethylidene)hydrazinecarbothioamide (acetylethTSC), were also prepared. All ligands were characterized by FT IR and electrochemistry. N-Ethhymethohcarbthio were characterized by elemental analysis whereas the reduced Schiff base and K[(Sal-L-tryp)] were characterized by ESI MS. X-ray crystallography was also used to characterize acetylethTSC. The ligands were then reacted with [VO(Sal-L-tryp)(H2O)] (1) (Sal-L-tryp = N-salicylidene-L-tryptophanate) to produce the novel complexes, [VO(Sal-L-tryp)(MeATSC)].1.5C2H5OH (2), [VO(Sal-L-tryp)(N-Ethhymethohcarbthio)].H2O (3), and [VO(Sal-L-tryp)(acetylethTSC)].0.75C2H5OH (4), respectively. All complexes were characterized by elemental analysis, ESI MS, IR, UV-visible, 1H and 13C NMR spectroscopy, and electrochemistry. Oxidized DMSO and DMSO-d6 solutions of each complex were also characterized by ESI MS and 1H NMR spectroscopy. [VO(Sal-L-tryp)(MeATSC)].1.5C2H5OH, [VO(Sal-L-tryp)(N-Ethhymethohcarbthio)].H2O, and [VO(Sal-L-tryp)(acetylethTSC)].0.75C2H5OH were observed to exhibit anti-proliferative activity against three colon cancer cell lines, HTC-116, Caco-2, and HT-29. When the anti-proliferative effects were compared with that of non-cancerous colonic myofibroblasts, less inhibition was observed. The results obtained suggest that these compounds can be used as potential chemotherapeutic agents.
"]},{"key":"dc:title","label":"Title","values":["Chemical, Biological, and Preliminary In Vitro Studies of Novel Vanadium(IV) Complexes with Schiff Bases and Thiosemicarbazone Ligands"]}]}],"canonical_facts":{"dc:contributor":["Alvin A. Holder","Douglas S. Masterson","Wujian Miao"],"dc:creator":["Lewis, Nerissa Abigail"],"dc:date.available":["2016-08-12T07:00:00Z"],"dc:description.abstract":["9-Anthraldehyde-N(4)-methylthiosemicarbazone (MeATSC), potassium (E)-2-(2-hydroxybenzylideneamino)-3-(1H-indol-3-yl)propanoate (K[(Sal-L-tryp)] and 2-(2-hydroxybenzylamino)-3-(1H-indol-3-yl)propanoic acid (the reduced Schiff base) were prepared using known synthetic procedures. Two novel thiosemicarbazone ligands, (E)-N-ethyl-2-(4-hydroxy-3-methoxybenzylidene)hydrazinecarbothioamide (N-Ethhymethohcarbthio) and (E)-N-ethyl-2-(1-(thiazol-2-yl)ethylidene)hydrazinecarbothioamide (acetylethTSC), were also prepared. All ligands were characterized by FT IR and electrochemistry. N-Ethhymethohcarbthio were characterized by elemental analysis whereas the reduced Schiff base and K[(Sal-L-tryp)] were characterized by ESI MS. X-ray crystallography was also used to characterize acetylethTSC. The ligands were then reacted with [VO(Sal-L-tryp)(H2O)] (1) (Sal-L-tryp = N-salicylidene-L-tryptophanate) to produce the novel complexes, [VO(Sal-L-tryp)(MeATSC)].1.5C2H5OH (2), [VO(Sal-L-tryp)(N-Ethhymethohcarbthio)].H2O (3), and [VO(Sal-L-tryp)(acetylethTSC)].0.75C2H5OH (4), respectively. All complexes were characterized by elemental analysis, ESI MS, IR, UV-visible, 1H and 13C NMR spectroscopy, and electrochemistry. Oxidized DMSO and DMSO-d6 solutions of each complex were also characterized by ESI MS and 1H NMR spectroscopy. [VO(Sal-L-tryp)(MeATSC)].1.5C2H5OH, [VO(Sal-L-tryp)(N-Ethhymethohcarbthio)].H2O, and [VO(Sal-L-tryp)(acetylethTSC)].0.75C2H5OH were observed to exhibit anti-proliferative activity against three colon cancer cell lines, HTC-116, Caco-2, and HT-29. When the anti-proliferative effects were compared with that of non-cancerous colonic myofibroblasts, less inhibition was observed. The results obtained suggest that these compounds can be used as potential chemotherapeutic agents.
"],"dc:identifier":["https://aquila.usm.edu/masters_theses/212"],"dc:subject":["vitro studies","novel vanadium (IV) complexes","schiff bases","thiosemicarbazone ligands","Chemistry"],"dc:title":["Chemical, Biological, and Preliminary In Vitro Studies of Novel Vanadium(IV) Complexes with Schiff Bases and Thiosemicarbazone Ligands"],"thesis:degree_discipline":["Chemistry and Biochemistry"],"thesis:degree_level":["Masters Thesis"],"thesis:degree_name":["Master of Science (MS)"]},"updated_at":"2026-07-24T05:44:41Z"}